-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The pathogenesis of systemic lupus erythematosus (SLE) involves a variety of disorders of innate and adaptive immune pathways
The pathogenesis of systemic lupus erythematosus (SLE) involves a variety of disorders of innate and adaptive immune pathways
Previous studies have shown that the risk of cardiovascular disease (CVD) and premature atherosclerosis is significantly increased in SLE, especially in young women
The risk of cardiovascular disease (CVD) and premature atherosclerosis is significantly increased in SLE, especially in young women
Researchers found that abnormal IFN-neutrophil interactions can increase the risk of CVD
Tofacitinib inhibits the phosphorylation of STAT1 in CD4+ T cells
Tofacitinib inhibits the phosphorylation of STAT1 in CD4+ T cellsThe main outcome of this trial is the safety and tolerability of tofacitinib
Tofacitinib can regulate circulating LDGs and NETs
Tofacitinib can regulate circulating LDGs and NETsAll in all, the results of the study revealed that the overall safety and tolerability of short-term use of tofacitinib in subjects with mild to moderate SLE was good, and there were no related adverse events
The overall safety and tolerability of short-term use of tofacitinib in subjects with mild to moderate SLE was good, and there were no related adverse events
Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus
Leave a message here
